Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacotherapy ; 19(12): 1445-9, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10600095

ABSTRACT

Five patients from a single institution received concomitant warfarin and 5-fluorouracil (5-FU) during a 3-year period. The mean weekly warfarin dose before starting chemotherapy was 40.66 mg and during chemotherapy it was 24 mg (p=0.0026). All patients required a warfarin dosage reduction (range 18-74%, mean 44%). Two patients were hospitalized, one with a major retroperitoneal bleed, the other for fresh-frozen plasma administration and observation. Maximum international normalized ratios (INRs) ranged from 3.66-23.7. This series confirms a common, clinically significant interaction between warfarin and 5-FU. An interaction between capecitabine, the orally available prodrug of 5-FU, and warfarin also has been reported. We recommend weekly monitoring of prothrombin time and INR for all patients receiving concomitant warfarin and 5-FU or capecitabine.


Subject(s)
Anticoagulants/adverse effects , Antineoplastic Agents/adverse effects , Deoxycytidine/analogs & derivatives , Fluorouracil/adverse effects , Warfarin/adverse effects , Anticoagulants/therapeutic use , Antineoplastic Agents/therapeutic use , Capecitabine , Deoxycytidine/adverse effects , Deoxycytidine/therapeutic use , Drug Interactions , Fluorouracil/therapeutic use , Humans , Prothrombin Time , Retroperitoneal Space/pathology , Time Factors , Warfarin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...